See more : TGS ASA (TGS.OL) Income Statement Analysis – Financial Results
Complete financial analysis of Heron Therapeutics, Inc. (HRTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Heron Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- DS Smith Plc (SMDS.L) Income Statement Analysis – Financial Results
- Pure Capital Solutions Inc. (PCST) Income Statement Analysis – Financial Results
- Ensurge Micropower ASA (ENMPF) Income Statement Analysis – Financial Results
- Qingdao TGOOD Electric Co., Ltd. (300001.SZ) Income Statement Analysis – Financial Results
- Sunshine Oilsands Ltd. (2012.HK) Income Statement Analysis – Financial Results
Heron Therapeutics, Inc. (HRTX)
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 127.04M | 107.67M | 86.35M | 88.64M | 145.97M | 77.47M | 30.77M | 1.28M | 0.00 | 0.00 | 0.00 | 0.00 | 646.00K | 1.30M | 1.26M | 369.00K | 412.00K | 0.00 | 5.39M | 5.40M | 4.85M | 5.82M | 4.39M | 3.37M | 20.40M | 20.00M | 18.30M | 18.70M | 16.10M | 15.90M | 19.90M | 7.30M | 2.80M | 2.40M | 2.80M | 2.50M | 1.70M |
| Cost of Revenue | 65.11M | 54.87M | 46.02M | 36.19M | 61.62M | 27.51M | 4.59M | 35.00K | 734.00K | 54.83M | 30.92M | 14.08M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 445.00K | 440.27K | 613.20K | 6.40M | 5.70M | 6.00M | 9.40M | 9.80M | 9.00M | 11.60M | 3.80M | 1.10M | 1.20M | 700.00K | 600.00K | 400.00K |
| Gross Profit | 61.94M | 52.80M | 40.33M | 52.45M | 84.35M | 49.96M | 26.18M | 1.24M | -734.00K | -54.83M | -30.92M | -14.08M | 646.00K | 1.30M | 1.26M | 369.00K | 412.00K | 0.00 | 5.39M | 5.40M | 4.85M | 5.37M | 3.95M | 2.75M | 14.00M | 14.30M | 12.30M | 9.30M | 6.30M | 6.90M | 8.30M | 3.50M | 1.70M | 1.20M | 2.10M | 1.90M | 1.30M |
| Gross Profit Ratio | 48.75% | 49.04% | 46.70% | 59.17% | 57.79% | 64.49% | 85.09% | 97.26% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% | 100.00% | 92.35% | 89.96% | 81.78% | 68.63% | 71.50% | 67.21% | 49.73% | 39.13% | 43.40% | 41.71% | 47.95% | 60.71% | 50.00% | 75.00% | 76.00% | 76.47% |
| Research & Development | 55.90M | 107.51M | 130.82M | 174.53M | 167.38M | 140.03M | 138.58M | 103.13M | 61.18M | 54.83M | 32.78M | 15.05M | 8.21M | 7.26M | 7.80M | 19.51M | 19.36M | 15.24M | 10.30M | 11.50M | 8.66M | 6.70M | 7.35M | 3.71M | 4.30M | 4.40M | 3.70M | 3.50M | 4.10M | 6.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 49.01M | 37.44M | 40.15M | 42.23M | 37.90M | 29.26M | 25.55M | 21.37M | 35.74M | 19.73M | 21.68M | 8.79M | 3.50M | 3.97M | 3.71M | 4.31M | 4.68M | 3.63M | 3.57M | 3.23M | 2.80M | 3.50M | 3.30M | 3.46M | 6.50M | 6.00M | 7.40M | 11.40M | 9.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 67.64M | 82.51M | 87.18M | 63.85M | 89.76M | 64.60M | 56.60M | 47.67M | 17.35M | 8.71M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 116.66M | 119.95M | 127.33M | 106.08M | 127.66M | 93.87M | 82.16M | 69.03M | 35.74M | 19.73M | 21.68M | 8.79M | 3.50M | 3.97M | 3.71M | 4.31M | 4.68M | 3.63M | 3.57M | 3.23M | 2.80M | 3.50M | 3.30M | 3.46M | 6.50M | 6.00M | 7.40M | 11.40M | 9.60M | 8.50M | 17.50M | 8.80M | 4.90M | 5.10M | 6.70M | 6.90M | 4.50M |
| Other Expenses | 0.00 | -7.37M | -2.86M | 885.00K | 5.95M | 5.10M | -38.00K | -2.23M | -666.00K | -1.81M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -116.76K | 500.00K | 1.40M | 1.20M | 1.40M | 1.20M | 1.10M | 1.20M | 1.10M | 800.00K | 800.00K | 700.00K | 900.00K | 900.00K |
| Operating Expenses | 172.55M | 227.46M | 258.15M | 280.61M | 295.04M | 233.90M | 220.74M | 172.16M | 96.93M | 74.56M | 54.46M | 23.83M | 11.71M | 11.24M | 11.50M | 23.81M | 24.05M | 18.86M | 13.86M | 14.72M | 11.46M | 10.19M | 10.65M | 7.06M | 11.30M | 11.80M | 12.30M | 16.30M | 14.90M | 15.90M | 18.70M | 9.90M | 5.70M | 5.90M | 7.40M | 7.80M | 5.40M |
| Cost & Expenses | 237.66M | 282.33M | 304.17M | 316.80M | 356.66M | 261.41M | 225.33M | 172.19M | 96.93M | 74.56M | 54.46M | 23.83M | 11.71M | 11.24M | 11.50M | 23.81M | 24.05M | 18.86M | 13.86M | 14.72M | 11.46M | 10.64M | 11.09M | 7.67M | 17.70M | 17.50M | 18.30M | 25.70M | 24.70M | 24.90M | 30.30M | 13.70M | 6.80M | 7.10M | 8.10M | 8.40M | 5.80M |
| Interest Income | 3.36M | 1.64M | 433.00K | 3.63M | 7.26M | 5.97M | 1.05M | 445.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.00K | 587.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 3.87M | 2.47M | 2.41M | 1.90M | 1.47M | 2.67M | 3.94M | 2.66M | 958.00K | 887.00K | 826.00K | 599.00K | 373.00K | 2.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.90M | 2.89M | 3.02M | 2.85M | 2.04M | 1.51M | 1.53M | 1.10M | 734.00K | 578.00K | 333.00K | 197.00K | 179.00K | 227.00K | 356.00K | 412.00K | 289.00K | -244.00K | 446.00K | 314.00K | 460.00K | 482.00K | 406.06K | -116.76K | 500.00K | 1.40M | 1.20M | 1.40M | 1.20M | 1.10M | 1.20M | 1.10M | 800.00K | 800.00K | 700.00K | 900.00K | 900.00K |
| EBITDA | -103.79M | -176.66M | -215.25M | -222.53M | -201.23M | -174.66M | -192.02M | -169.38M | -96.19M | -73.98M | -54.46M | -23.83M | -10.88M | -6.97M | -9.86M | -22.51M | -19.44M | 5.91M | -8.03M | -9.02M | -5.96M | -4.58M | -6.77M | -4.03M | -1.50M | -2.00M | -800.00K | -7.10M | -7.40M | -7.90M | -9.20M | -5.30M | -3.20M | -3.90M | -4.60M | -5.00M | -3.20M |
| EBITDA Ratio | -81.70% | -162.21% | -252.27% | -257.41% | -142.94% | -237.42% | -624.10% | -13,363.17% | 0.00% | 0.00% | 0.00% | 0.00% | -1,684.67% | -956.73% | -783.58% | -6,223.85% | -6,274.51% | 0.00% | -148.95% | -166.99% | -130.05% | -75.84% | -145.49% | -132.20% | 15.69% | 18.50% | 4.92% | -24.06% | -44.72% | -47.80% | -50.75% | -83.56% | -128.57% | -204.17% | -196.43% | -244.00% | -217.65% |
| Operating Income | -110.62M | -174.66M | -217.83M | -228.16M | -210.69M | -183.94M | -194.56M | -170.92M | -96.93M | -74.56M | -54.46M | -23.83M | -11.06M | -9.93M | -10.24M | -23.45M | -23.63M | -18.86M | -8.47M | -9.32M | -6.61M | -4.82M | -6.70M | -4.31M | 2.70M | 2.50M | -300.00K | -7.00M | -8.60M | -9.00M | -10.40M | -6.40M | -4.00M | -4.70M | -5.30M | -5.90M | -4.10M |
| Operating Income Ratio | -87.07% | -162.21% | -252.27% | -257.41% | -144.34% | -237.42% | -632.36% | -13,363.17% | 0.00% | 0.00% | 0.00% | 0.00% | -1,712.38% | -763.57% | -812.21% | -6,353.66% | -5,736.17% | 0.00% | -157.17% | -172.39% | -136.39% | -82.96% | -152.79% | -127.96% | 13.24% | 12.50% | -1.64% | -37.43% | -53.42% | -56.60% | -52.26% | -87.67% | -142.86% | -195.83% | -189.29% | -236.00% | -241.18% |
| Total Other Income/Expenses | 56.00K | -7.37M | -2.86M | 885.00K | 5.95M | 5.10M | -2.93M | -2.23M | -666.00K | -1.81M | -826.00K | -599.00K | -373.00K | 2.74M | 24.00K | 520.00K | 3.83M | 24.38M | 290.00K | 224.00K | 153.00K | 297.00K | 712.64K | 26.39K | 0.00 | 200.00K | 300.00K | 400.00K | -200.00K | -300.00K | 900.00K | 600.00K | 0.00 | 1.00M | 900.00K | 1.10M | 500.00K |
| Income Before Tax | -110.56M | -182.02M | -220.68M | -227.28M | -204.75M | -178.84M | -197.48M | -173.14M | -97.59M | -76.37M | -55.28M | -24.43M | -11.44M | -7.20M | -10.15M | -23.13M | -19.80M | 5.52M | -8.47M | -9.29M | -6.46M | -4.76M | -6.62M | -4.28M | 0.00 | 2.70M | 0.00 | -8.10M | -8.80M | -9.30M | -9.50M | -5.80M | -4.00M | -3.70M | -4.40M | -4.80M | -3.60M |
| Income Before Tax Ratio | -87.02% | -169.05% | -255.58% | -256.41% | -140.27% | -230.84% | -641.87% | -13,537.37% | 0.00% | 0.00% | 0.00% | 0.00% | -1,770.12% | -553.11% | -804.92% | -6,266.94% | -4,805.83% | 0.00% | -157.11% | -171.98% | -133.23% | -81.79% | -150.83% | -127.18% | 0.00% | 13.50% | 0.00% | -43.32% | -54.66% | -58.49% | -47.74% | -79.45% | -142.86% | -154.17% | -157.14% | -192.00% | -211.76% |
| Income Tax Expense | 0.00 | -47.51M | -3.02M | -2.85M | 1.87M | 7.77M | 3.90M | -1.10M | -734.00K | -578.00K | -333.00K | -1.28M | 379.00K | -2.59M | -122.00K | -320.00K | 41.00K | 119.00K | -263.00K | -95.00K | -2.25M | -1.05M | -4.19M | -12.86M | 300.00K | 600.00K | 700.00K | 2.40M | 800.00K | 800.00K | -500.00K | -200.00K | 300.00K | -800.00K | -800.00K | -900.00K | -300.00K |
| Net Income | -110.56M | -134.52M | -217.66M | -224.43M | -204.75M | -178.84M | -197.48M | -173.14M | -97.59M | -76.37M | -55.28M | -23.35M | -11.81M | -7.35M | -10.03M | -23.13M | -20.16M | 5.27M | -8.21M | -9.22M | -4.36M | -3.78M | -2.51M | 8.55M | 2.40M | 1.90M | -700.00K | -9.40M | -9.40M | -9.80M | -9.90M | -5.60M | -4.30M | -3.90M | -4.50M | -5.00M | -3.80M |
| Net Income Ratio | -87.02% | -124.93% | -252.08% | -253.20% | -140.27% | -230.84% | -641.87% | -13,537.37% | 0.00% | 0.00% | 0.00% | 0.00% | -1,828.79% | -564.64% | -795.24% | -6,266.94% | -4,893.93% | 0.00% | -152.29% | -170.63% | -90.00% | -64.97% | -57.29% | 254.09% | 11.76% | 9.50% | -3.83% | -50.27% | -58.39% | -61.64% | -49.75% | -76.71% | -153.57% | -162.50% | -160.71% | -200.00% | -223.53% |
| EPS | -0.80 | -1.24 | -2.21 | -2.47 | -2.50 | -2.44 | -3.65 | -4.57 | -2.95 | -2.87 | -3.42 | -1.91 | -1.96 | -3.70 | -6.15 | -15.01 | -20.83 | 66.70 | -26.15 | -32.20 | -16.98 | -14.81 | -9.92 | 33.60 | 9.60 | 10.40 | -2.88 | -40.96 | -45.69 | -48.87 | -58.03 | -34.50 | -34.40 | -32.14 | -37.86 | -43.99 | -35.08 |
| EPS Diluted | -0.80 | -1.24 | -2.21 | -2.47 | -2.50 | -2.44 | -3.65 | -4.57 | -2.95 | -2.87 | -3.42 | -1.91 | -1.96 | -3.70 | -6.15 | -15.01 | -20.83 | 66.25 | -26.15 | -32.20 | -16.98 | -14.81 | -9.92 | 33.60 | 9.60 | 9.60 | -2.88 | -40.96 | -45.69 | -48.87 | -58.03 | -34.50 | -34.40 | -32.14 | -37.86 | -43.99 | -35.08 |
| Weighted Avg Shares Out | 138.14M | 108.88M | 98.47M | 90.77M | 81.78M | 73.19M | 54.04M | 37.93M | 33.08M | 26.57M | 16.16M | 12.22M | 6.01M | 1.98M | 1.63M | 1.54M | 967.90K | 78.95K | 313.98K | 286.36K | 256.91K | 255.11K | 253.45K | 252.24K | 250.99K | 248.18K | 243.31K | 229.50K | 205.74K | 200.54K | 170.59K | 162.33K | 124.99K | 121.34K | 118.85K | 113.65K | 108.33K |
| Weighted Avg Shares Out (Dil) | 138.14M | 108.88M | 98.47M | 90.77M | 81.78M | 73.19M | 54.04M | 37.93M | 33.08M | 26.57M | 16.16M | 12.22M | 6.01M | 1.98M | 1.63M | 1.54M | 967.90K | 79.49K | 313.98K | 286.36K | 256.91K | 255.11K | 253.45K | 252.43K | 253.15K | 254.76K | 243.31K | 229.50K | 205.74K | 200.54K | 170.59K | 162.33K | 124.99K | 121.34K | 118.85K | 113.65K | 108.33K |
Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
- The VAN has the potential to simplify aseptic preparation, while also significantly reducing ZYNRELEF's withdrawal time - The VAN is expected to launch in Q4 2024 SAN DIEGO , Sept. 25, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX)...
Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer
SAN DIEGO , Sept. 3, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced today...
Heron Therapeutics (HRTX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Heron Therapeutics (HRTX) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street...
Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates
Heron Therapeutics (HRTX) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.35 per share a year ago.
Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance
Second quarter Net Product Sales of $36.0 million, which increased from $31.8 million for the same period in 2023 ZYNRELEF® Vial Access Needle ("VAN") PDUFA goal date set for September 23, 2024 ZYNRELEF included in the proposed 2025 Non-Opioid Policy...
Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024
SAN DIEGO , July 30, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company will host a conference call and live webcast on Tuesday, August 6, 2024, at 4:30 p.m. ET to...
Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System
SAN DIEGO , July 15, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that ZYNRELEF® (bupivacaine and meloxicam) is included in the proposed 2025 Non-Opioid Policy for Pain Relief under...
Heron Therapeutics (HRTX) Upgraded to Strong Buy: Here's What You Should Know
Heron Therapeutics (HRTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
New Strong Buy Stocks for July 11th
SKIL, INKT, MLCO, GTLB, and HRTX have been added to the Zacks Rank #1 (Strong Buy) List on July 11, 2024.
Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
-The U.S. Food and Drug Administration ("FDA") assigned a Prescription Drug User Fee Act ("PDUFA") goal date of September 23, 2024 SAN DIEGO , July 2, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage...
Source: https://incomestatements.info
Category: Stock Reports